Writer Toni Brown
MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report entitled “Thought Leader Insight & Analysis: Hepatitis C Virus (HCV),” designed to provide critical strategic insight for pharma and biotech companies with a stake in the market for treatments in this disease area.
“This report summarizes the perspectives of renowned thought leaders who specialize in the treatment of hepatitis C,” according to Elizabeth Mathews, MedPredict’s CEO. “We conducted in-depth interviews with these experts immediately following AASLD to understand the effect that the upcoming approvals of telaprevir and boceprevir will have on the treatment of HCV, as well as to gain insight into how combination therapy will address the unmet needs still remaining after the approval of these protease inhibitors.”
Some of the topics discussed by in this report include:
- Goals of therapy,
- Who should treat HCV,
- Unmet needs and favorite future cocktails; interferon-sparing regimens,
- Warehousing patients in the age of protease inhibitors,
- Potential for resistance development,
- Dosing/compliance,
- IL-28b / CC, CT and TT patients; US, EU and Asian populations,
- Fibrosis score,
- Possible reimbursement/bundling strategies,
- Cost of therapy and duration of treatment, and
- Side effects: rash vs. anemia.
The full report may be purchased by contacting MedPredict.
About MedPredict
MedPredict maintains a proprietary database of over 1,000 global physician thought leaders. Based on primary interviews with these thought leaders, MedPredict publishes periodic therapeutic area reports to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and presentations, as well as clinical, regulatory and marketing activity.
For more information contact:
Elizabeth Mathews
MedPredict
513.271.1924
Source
No comments:
Post a Comment